Functional crosstalk between WNT activity and PD-L1 expression is the basis for the use of selective WNT activators or inhibitors to up- or downregulate PD-L1 expression, respectively, in triple-negative breast cancer (TNBC) stem cells, holding the promise of immunotherapy for this cancer [46]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.